XBiotech (XBIT) Treats First Patient in 514G3 Phase 1/2 for Staph Infections
Tweet Send to a Friend
XBiotech (NASDAQ: XBIT) announced that treatment of first patient in its Phase 1/2 clinical study. The study is designed to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
